c Introdu

ing
Tablets / Syrup

Rytopod
Cefpodoxime + Clavulanic Acid

For the treatment of

Purulent Rhino-sinusitis, Tonsillitis, Pharyngitis and Otitis Acute Infected Bronchitis, Acute Exacerbation of Chronic Bronchitis (AECB) and Pneumonia Pyelonephritis, Urethritis, Ureteritis

When new beta-lactamases raise their ugly heads continuously...

Clavulanic acid added to Cefpodoxime

Demonstrates synergy which decreases MIC of even resistant organisms Expands spectrum by making those organisms responsive which do not respond to Cefpodoxime alone

Dosage: Adult - 1 Tab - Twice Daily for 7 to 10 Days Children - 10 mg/kg/day divided every 12 hours

Rx

Rytopod
Tablets / Syrup

Rytopod - The Dependable Broad-Spectrum Antibiotic

...Can hydrolyze even advanced-spectrum Cephalosporins

AmpC cephalosporinases produced 1 in high quantities KPC beta-lactamases seen worldwide in pan-resistant 2 gram-negative pathogens Metallo-beta-lactamases causes 3 resistance to all beta-lactams

Multidrug resistance is observed in most isolates Eradication of these resistant strains is challenging
There is an acute need to combine Clavulanic Acid with Cefpodoxime
Ref.: 1. Crit Care. 2010; 14(3):224. Epub 2010 Jun 29. 2. Clin Microbiol Infect 2008; 14 (Suppl. 1): 189-193 3. BMC Infectious Diseases 2009, 9:61 doi:10.1186/1471-2334-9-61

Make a dependable choice

ucing Introd

Rytopod
Cefpodoxime + Clavulanic Acid
Medication Cefprozil + + + + + Cefpodoxime Proxetil + + + + + + + + + + Cefuroxime + + + + + + + + Cefadroxil + + + + + +

Tablets / Syrup

Cefpodoxime coverage outshines cefixime and cefuroxime

Cefixime Staphylococcus Aureus Staphylococcus Saprophyticus Staphylococcus Pneumonlae Staphylococcus Pyogenes Enterococcus Species Escherichia Coli Haemophilus Influenzae Kiebsiella Pneumoniae Moraxella Catarrhalis Neisseria Gonorrhoeae Proteus Mirabllis + + + + + +

Clavulanic Acid - The Armour that protects the Knight Cefpodoxime

Clavulanic acid binds to and inactivates wide range of beta-lactamases and prevents destruction of cefpodoxime Demonstrates synergy with Cefpodoxime by lowering MIC of non-susceptible pathogens
MIC values in g/ml Micro-organism Citrobacter amalonaticus 4026 Citrobacter freundii 3757 Enterobacter aerogenes 3701 Enterobacter cloacae 53 Enterobacter cloacae 3146 Proteus mirabilis 3750 Proteus penneri 1767 Cefpodoxime 8 (Resistant) 128 (Resistant) 32 (Resistant) 32 (Resistant) 64 (Resistant) 8 (Resistant) 32 (Resistant) 1 (Susceptible) 128 (Resistant) 128 (Resistant) >128 (Resistant) >128 (Resistant) >128 (Resistant) 4 (Intermediate) 2 (Susceptible Cefpodoxime + Clavulanic acid 2 8 < 0.06 _ 0.5 2 < 0.06 _ < 0.06 _ 0.12 < 0.06 _ < 0.06 _ 0.12 4 4 0.25 0.5

*Plus sign indicated coverage; minus sign, no coverage. No in vivo data were available; however, in vitro data indicate organisms are susceptible.

Cefpodoxime is thus one of the most active Cephalosporin compounds

Proteus vulgaris 1781 Proteus vulgaris 1405 Proteus vulgaris 1699 Proteus vulgaris 1765 Serratia marcescens 91 Serratia marcescens 167 Serratia rubidaea 3139 Serratia rubidaea 3134

Adapted From: Journal Of Clinical Microbiology Jan 2004 p294 -298

Rytopod, The Dependable Broad-Spectrum Antibiotic

ucing Introd

Rytopod
Cefpodoxime + Clavulanic Acid

Tablets / Syrup

In demanding Upper Respiratory Tract Infections

Chronic Purulent Rhino-sinusitis Purulent Tonsillitis Pharyngitis Otitis media

Pathogens in the community acquired URTI are now strengthened by Beta-Lactamases

In S. pneumoniae, penicillin resistance has negligible influence on cefpodoxime compared to cefixime, cefaclor and cefuroxime1 In beta-lactamase producing H. influenza, rank order of activity of Cefpodoxime was highest compared to other Cephalosporin2
Ref 1: Prous Science 2006; Vol.19 (N 1): 39-44 Ref 2: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1997, p. 292297

Rytopod, The Dependable Broad-Spectrum Antibiotic

ucing Introd

Rytopod
Cefpodoxime + Clavulanic Acid

Tablets / Syrup

In demanding Lower Respiratory Tract Infection like

Acute Infected Bronchitis Acute Exacerbation of Chronic Bronchitis (AECB) Pneumonia

Higher Clinical Success

Positive Clinical outcome of 99% Microbiological cure rate of more than 90%1
1

Cefpodoxime demonstrates

Broad Spectrum anti-bacterial activity Distinctly balanced coverage against gram +ve and gram -ve pathogens Ideal step down treatment from injectable Lowest MIC values against gram +ve bacteria

Pathogens in the community acquired LRTI are now strengthened by Beta-Lactamases

High stability against most Beta-Lactamases Exceptional activity against Staphylococci, Streptococci and Major Gram -ve pathogens
Ref. : 1. Chest 1993; 104:1387-92 2. Antimicroblal Agents And Chemotherapy, Oct. 1992, p. 2099-2103

Rytopod, The Dependable Broad-Spectrum Antibiotic

ucing Introd

Rytopod
Cefpodoxime + Clavulanic Acid
60 third-gen.cephalosporin 50 fluoroquinolone aminopenicillin

Tablets / Syrup

In demanding Urinary Tract Infection

Pyelonephritis Urethritis
Percentage Resistant

Percentage of resistance to fluoroquinolones, third-generation cephalosporines and 2 aminopenicillins in E. coli

Ureteritis
Pathogens in the community acquired UTI are now strengthened by Beta-Lactamases A Significant rise in resistance of E. Coli to third generation Cephalosporin Incidences of Beta-Lactamase producing invasive E-Coli, resistant to third-generation 1 Cephalosporins have risen beyond 10%
Ref. : 1. Urology 2006, 68(6):1169-1174

40

30

20

10

2001

2002

2003

2004

2005

2006

2007

Year

Ref. : 2. BMC Infectious Diseases 2009, 9:61 doi: 10.1186/1471-2334-9-61

Rytopod, The Dependable Broad-Spectrum Antibiotic